PMID- 30510450
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 10
DP  - 2018
TI  - Distinct prognostic value of dynactin subunit 4 (DCTN4) and diagnostic value of 
      DCTN1, DCTN2, and DCTN4 in colon adenocarcinoma.
PG  - 5807-5824
LID - 10.2147/CMAR.S183062 [doi]
AB  - BACKGROUND: Colon adenocarcinoma (COAD) is ranked as the third most commonly 
      diagnosed cancer in both women and men, and it is the most frequently occurring 
      malignant tumor. Dynactin is a protein compound based on multiple subunits, 
      including dynactin 1-6 (DCTN1-6), in most categories of cytoplasmic dynein 
      performance in eukaryotes. Nevertheless, correlations between the DCTN family and 
      the prognosis and diagnosis of COAD remain unidentified. METHODS: Statistics for 
      DCTN mRNA expression in patients with COAD were acquired from The Cancer Genome 
      Atlas. Kaplan-Meier analyses and a Cox regression model were applied to determine 
      overall survival, with computation of HRs and 95% CIs. Several online data 
      portals were used to assess the biological process, and pathway examination was 
      performed using the Kyoto Encyclopedia of Genes and Genomes to predict the 
      biological functionality of DCTN genes. RESULTS: We found that high expression of 
      DCTN4 was linked with satisfactory results for overall survival (P=0.042, 
      HR=0.650, 95% CI 0.429-0.985). The expression of DCTN1, DATN2, and DCTN4 was 
      closely correlated with the frequency of colon tumors (P<0.001, area under the 
      curve [AUC]=0.8811, 95% CI 0.8311-0.9312; P<0.001, AUC=0.870, 96% CI 
      0.833-0.9071; and P=0.0051, AUC=0.6317, 95% CI 0.5725-0.6908, respectively). In 
      the enrichment examination, the level of gene expression was related to the cell 
      cycle, cell apoptosis, and the cell metastasis pathway. CONCLUSION: The 
      expression levels of DCTN1, DCTN2, and DCTN4 could allow differentiation between 
      cancer-bearing tissues and paracancerous tissue. These genes can be applied as 
      biomarkers to predict the prognosis and diagnosis of COAD.
FAU - Wang, Shijun
AU  - Wang S
AD  - Department of Colorectal and Anal Surgery, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, Henan Province, China, 13673384555@163.com; 
      banichonghuai0910@163.com.
FAU - Wang, Qiaoqi
AU  - Wang Q
AD  - Department of Medical Cosmetology, The Second Affiliated Hospital of Guangxi 
      Medical University, Nanning, Guangxi Province, China.
FAU - Zhang, Xiqian
AU  - Zhang X
AD  - Department of Radiotherapy, The First Affiliated Hospital of Zhengzhou 
      University, Henan Province, China.
FAU - Liao, Xiwen
AU  - Liao X
AD  - Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi 
      Medical University, Nanning, Guangxi Province, China.
FAU - Wang, Guixian
AU  - Wang G
AD  - Department of Colorectal and Anal Surgery, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, Henan Province, China, 13673384555@163.com; 
      banichonghuai0910@163.com.
FAU - Yu, Long
AU  - Yu L
AD  - Department of Hepatobiliary Surgery, The First Affiliated Hospital of Zhengzhou 
      University, Henan Province, China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Colorectal and Anal Surgery, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, Henan Province, China, 13673384555@163.com; 
      banichonghuai0910@163.com.
FAU - Zhou, Quanbo
AU  - Zhou Q
AD  - Department of Colorectal and Anal Surgery, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, Henan Province, China, 13673384555@163.com; 
      banichonghuai0910@163.com.
FAU - Hu, Shengyun
AU  - Hu S
AD  - Department of Colorectal and Anal Surgery, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, Henan Province, China, 13673384555@163.com; 
      banichonghuai0910@163.com.
FAU - Yuan, Weitang
AU  - Yuan W
AD  - Department of Colorectal and Anal Surgery, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, Henan Province, China, 13673384555@163.com; 
      banichonghuai0910@163.com.
LA  - eng
PT  - Journal Article
DEP - 20181116
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC6248376
OTO - NOTNLM
OT  - biomarker
OT  - colon adenocarcinoma
OT  - diagnosis
OT  - dynactin
OT  - prognosis
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/12/05 06:00
MHDA- 2018/12/05 06:01
PMCR- 2018/11/16
CRDT- 2018/12/05 06:00
PHST- 2018/12/05 06:00 [entrez]
PHST- 2018/12/05 06:00 [pubmed]
PHST- 2018/12/05 06:01 [medline]
PHST- 2018/11/16 00:00 [pmc-release]
AID - cmar-10-5807 [pii]
AID - 10.2147/CMAR.S183062 [doi]
PST - epublish
SO  - Cancer Manag Res. 2018 Nov 16;10:5807-5824. doi: 10.2147/CMAR.S183062. 
      eCollection 2018.